Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
Pre-market:
| Previous close | 354.81 |
| Open | 355.11 |
| Bid | 0.00 x 900 |
| Ask | 358.00 x 800 |
| Day's range | 350.26 - 356.46 |
| 52-week range | 282.21 - 387.42 |
| Volume | |
| Avg. volume | 1,208,615 |
| Market cap | 90.488B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 26.38 |
| EPS (TTM) | 13.31 |
| Earnings date | 05 Feb 2024 - 09 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 400.00 |
Motley FoolYou Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Motley FoolA Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own.
These stocks are already big winners in 2023 and should keep their momentum going in a new bull market.
Motley FoolWhere Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the disease that together generate blockbuster revenue . Now, whether you're a Vertex investor or a potential one, you may be wondering what's next for this big biotech.
© 2023 Yahoo. All rights reserved.